tert-butyl (S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate

Catalog No. :
ACNFBZ982
CAS No. :
1642571-08-1
Molecular Formula :
C27H30N6O3
Molecular Weight :
486.58

IUPAC Name:tert-butyl (S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate

tert-butyl (S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl (S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
IUPAC Nametert-butyl (S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
Molecular FormulaC27H30N6O3
Molecular Weight486.58
SMILESCC(C)(C)OC(=O)N1CCC[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1
InChI KeyNTSAEGNFPKKRLX-IBGZPJMESA-N
SynonymIbrutinib Impurity 21;(S)-tert-butyl 3-(4-amino-3-(4-phenoxyphenyl);1-Piperidinecarboxylic acid, 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, 1,1-dimethylethyl ester, (3S)-
CAS No.1642571-08-1

Synthetic Route by SureRoute

1. ACNFBZ982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMIAH639 route compound structure diagram
    ACMIAH639461702-66-9 In Stock
  2. Plus
  3. ACHOZW985 route compound structure diagram
    ACHOZW985269410-26-6 In Stock
  4. Then
  5. ACNFBZ982 route product structure diagram
    ACNFBZ9821642571-08-1
Inquiry

2. ACNFBZ982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACHOZW985 route compound structure diagram
    ACHOZW985269410-26-6 In Stock
  4. Then
  5. ACNFBZ982 route product structure diagram
    ACNFBZ9821642571-08-1
Inquiry

Comments (0)